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ABSTRACT
Background: No susceptibility genes have been identi-
fied in human prion disase, apart from the prion protein
gene (PRNP). The gene SPRN, encodes Shadoo (Sho,
shadow of prion protein) which has protein homology and
possible functional links with the prion protein.
Methods: A genetic screen was carried out of the open
reading frame of SPRN by direct sequencing in 522
patients with prion disease, including 107 with variant
Creutzfeldt–Jakob disease (vCJD), and 861 healthy
controls.
Results: A common coding variant of SPRN, two further
single nucleotide polymorphisms (SNPs) and three rare
insertion or deletion variants were found. A single base-
pair insertion at codon 46, predicted to cause a frameshift
and potentially a novel protein, was found in two patients
with vCJD but not in controls (p=0.01). Two linked
SNPs, one in intron 1 and the other a missense variant at
codon 7, were associated with risk of sporadic CJD
(p=0.009).
Conclusion: These data justify the functional genetic
characterisation of SPRN and support the involvement of
Shadoo in prion pathobiology.
Despite clear evidence from mouse linkage studies
of multiple genetic loci affecting incubation periods
of prion diseases,
12no specific human genes have
been identified, apart from the prion protein gene
(PRNP). A recently characterised highly conserved
gene, SPRN, encodes Shadoo (Sho, shadow of prion
protein) which has protein homology and possible
functional links with the prion protein.
3
Human prion diseases are a phenotypically
diverse range of fatal neurodegenerative disorders
that are unique in having sporadic, acquired and
inherited aetiologies.
4 Common to the pathogen-
esis of all prion diseases is a central role for the
autocatalytic misfolding of the prion protein (PrP).
5
These uncommon neurodegenerative diseases have
come under close scrutiny in recent years because
of a public health threat related to the epizootic of
bovine spongiform encephalopathy (BSE), its
human counterpart variant Creutzfeldt–Jakob dis-
ease (vCJD)
6–8 and the subsequent secondary
transmission of vCJD by blood transfusion.
9
Sporadic forms of human prion disease account
for approximately 85% of total prion disease cases,
most typically appearing as a rapidly progressive
multifocal dementia with myoclonus (sCJD).
Multiple distinct prion strains in sporadic disease
associate with a variety of clinicopathological
phenotypes.
10 Conversely, vCJD is associated with
a distinct and unique prion strain, and has been
described to date in around 200 patients worldwide
with most (.160 cases) occurring in the UK. As a
group, patients with vCJD differ from those with
sCJD in their relatively early age of onset and
longer duration, prominent psychiatric and sensory
features at presentation, and characteristic neuro-
pathology and prominent lymphoreticular prion
infection.
11
Although there is only one known familial
concurrence of vCJD, there is a strong likelihood
that genetic susceptibility has played a part in
determining why particular individuals succumbed
following the widespread population exposure to
dietary BSE prions. Epidemiological case control
studies have shown no clear-cut evidence for
unusual dietary or occupational exposure.
12 PRNP
is polymorphic in Europeans at codon 129,
between methionine (,60% allele frequency) and
valine. All clinical vCJD cases examined have been
homozygous for methionine,
13 representing the
strongest association of a common genotype with
any disease. Support for the existence of novel
genetic factors is derived from mouse quantitative
locus studies, which have shown multiple regions,
unlinked to Prnp, that control the incubation time
to BSE prions.
11 41 5
The normal function of PrP, its molecular
interactions in the healthy cell, and its pathogen-
esis and neurotoxic pathways remain unclear.
Proteins encoded by genetic loci that modify
susceptibility to, or incubation time in, prion
disease might do so by involvement with the
normal functional pathways of PrP, either as a
ligand or homologue, and several putative PrP
ligands have been proposed.
16 The recently char-
acterised prion protein family,
17 including Doppel
18
and Shadoo,
19 are pre-eminent candidate functional
homologues of PrP, but several lines of evidence
contradict involvement of PRND genetic variation
and Dpl in human prion disease.
17 20 21
SPRN, the gene encoding Sho, was identified by
comparative gene analysis, and this gene and its
encoded protein have several characteristics sug-
gestive of a role in prion biology.
19 The SPRN gene
comprises two exons, the latter containing the
entire open reading frame (ORF). Also in common
with PRNP, high levels of conservation of this gene
exist between many species from fish to mam-
mals,
22 with highest levels of SPRN conservation
present in its hydrophobic domain. In addition,
both proteins are predicted to have glycopho-
sphotidylinositol (GPI) anchor attachment, a single
transmembrane domain and a highly conserved N-
terminal sequence. Recent work has shown over-
lapping expression patterns of PrP and Sho in the
CNS, the similarity of Sho transgenes to PrP in
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Doppel or aminoterminal truncated PrP, and reduced levels of
Sho in experimental prion infection. It has therefore been
hypothesised that Sho may interact either directly or indirectly
with PrP or its ligand.
3 In this study, we provide new evidence of
a role for SPRN in prion pathobiology by showing that Sho
variants are associated with two human prion diseases.
METHODS
Ethics approval was obtained from the UCL Institute of
Neurology and National Hospital for Neurology and
Neurosurgery Local Research Ethics Committee, and all
participants gave informed consent.
The study comprised patients with sCJD, patients with vCJD
and a control group. The sCJD group comprised 415 patients,
who were definite or probable cases of sCJD according to World
Health Organization (WHO) diagnostic criteria. The 107
definite or probable patients with vCJD studied also met
WHO diagnostic criteria and were diagnosed either by tonsillar
biopsy, post-mortem analysis of brain tissue, or established
clinical criteria and imaging findings. The control cohort
consisted of 92 healthy UK controls matched for age and sex
to the patients with vCJD, 137 UK healthy blood donor
controls, 446 UK healthy controls from the European Collection
of Cell Cultures (ECACC) collection, and 186 unrelated healthy
control individuals from the Centre d’Etude du Polymorphisme
Humain (CEPH) collection.
We performed direct gene resequencing on peripheral blood
samples from cases and controls to investigate the possibility of
a significant association between genetic variation within the
SPRN ORF and susceptibility to sCJD or vCJD. Genomic DNA
was isolated using a commercial extraction kit (Nucleon
BACC2; GE Healthcare UK, Little Chalfont, Buckinghamshire,
UK) following the supplied protocol. DNA concentrations were
determined using a spectrophotometer (Nanodrop ND-1000;
Thermo Fisher Scientific, Waltham, Massachusetts, UK), and
diluted in Tris/EDTA buffer in aliquots of 20 ng/ml to prepare
96-well plates for PCR.
For DNA sequencing, oligonucleotide primers were designed
to amplify two overlapping amplicons to span the entire ORF
and were designed using DNA sequence from reference contig
accession number AL161645 (exact location of primers with
reference to AL161645 are given in parentheses after each primer
described below). Amplicon 1 was 359 bp (2100 bp to +259 bp)
and amplified with sense 59-CCTCTGCTCTCCAGCCTTG-39
(8404-8422) and antisense 59-AGCCCGCCGCCAGGCC-39
Table 1 Genetic variants found in the study
Variation
Key
Allele counts Haplotypes and frequency
DNA Protein
vCJD
(n=107)
sCJD
(n=415)
HC
(n=861) *1 *1A *1B *2 *2A *2B *2C
59-11ARG – A:G 152:62 598:232 1155:567 AAAGGGG
c.20CRT p.Thr7Met T:C 152:62 598:232 1155:567 TTTCCCC
c.136_137insG p.Ala46GlyfsX294 wt:ins 212:2 830:0 1722:0 wt wt wt wt wt insw t
c.183CRT – C:T 171:43 672:158 1344:378 CCCTCTC
c.216_227delAGC
CGGGGCGGC
p.Ala72_Ala75del wt:del 214:0 830:0 1718:4 wt del1 wt wt wt wt del1
c.239_240insGGC
GGGAGCGGC
p.Ala79_Ala80ins
AlaAlaGlyAla
wt:ins 214:0 830:0 1721:1 wt wt ins wt wt wt wt
vCJD 152{
(71)
0{ 0{ 41{
(19)
19{
(9)
2{
(1)
0{
sCJD 598{
(72)
0{ 0{ 158{
(19)
74{
(9)
0{ 0{
Control 11511
(67)
31
(,1)
11
(,1)
3791
(22)
1871
(11)
01 11
(,1)
del, Deletion; HC, healthy controls; ins, insertion; sCJD, sporadic Creutzfeldt–Jakob disease; vCJD, variant Creutzfeldt–Jakob disease; wt, wild type.
{vCJD.
{sCJD.
1Healthy controls.
Individual haplotypes and their frequencies, given as counts with percentages in parentheses, are displayed vertically, calculated by expectation-maximisation algorithm
(Haploview).
Alleles and allele counts, together with a key to the allele counts, are displayed horizontally.
Insertion and deletion alleles are coded as wild type (wt) or ‘ins/del’ depending on the absence or presence of the indel variation compared with contig AL161645, respectively.
Table 2 Results from tests performed using genotypic and allelic (trend) models
Variation MAF
Model
Genotypic Allelic (trend)
Counts x
2 p Value Counts x
2 p Value
59-11ARG/c.20TRC 0.29 vCJD 11/40/56 3.655 0.16 62/152 1.43 0.23
0.28 sCJD 30/172/213 7.135 0.028 232/598 6.8 0.009
0.33 Control 81/405/375 – – 567/1155 – –
c.136_137insG 0.01 vCJD 0/2/105 NA NA 2/212 16.1 0.01{
0 sCJD 0/0/415 NA NA 0/830 NA NA
0 Control 0/0/861 – – 0/1722 – –
NA, not applicable; sCJD, sporadic Creutzfeldt–Jakob disease; vCJD, variant Creutzfeldt–Jakob disease.
{Denotes Fisher Exact test applied because cell counts were small. Genotypic counts and allelic counts are displayed AA/AB/BB
and A/B respectively, where A=59-11G (c.20C) or c.136_137insG.
Bold type denotes significance.
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and amplified with sense 59-CTTCCTCTGCGACAGCGGCG-
39 (8257–8276) and antisense 59-GCGATGGAGCGTGGC-
TGGG-39 (7566–7585). PCR reactions containing a final
concentration of 1 mol/l betaine were thermally cycled with
an initial denaturation step at 95uC for 5 minutes, followed by
35 cycles of 95uC for 30 s, 65.5uC (amplicon 1) or 63.1uC
(amplicon 2) for 30 s and 72uC for 45 s, and then a final
extension step at 72uC for 5 minutes. Cleaned PCR products
were sequenced in reactions including betaine 1 mol/l (final
concentration) and separated by electophoresis on an auto-
mated sequencer (3130xl; Applied Biosystems, Foster City,
California, USA). Data analysis was performed using Seqscape
software V.2.5 (Applied Biosystems) with analysis filter settings
adjusted to allow assembly of poor data due to insertions of
deletions (maximum mixed bases 95%, maximum uncalled
bases 95%, minimum clear length of 1 bp, and minimum sample
score of 1). Poor data or failed reactions were removed from
projects by visual inspection. To assess the expression level of
the frameshift allele (p.Ala46GlyfsX294) in postmortem frontal
cortex, total RNA was extracted from 100 mg of frozen tissue
using (TRIzol Plus Purification kit; Invitrogen, Paisley, UK). A
commercial kit (Omniscript Reverse Transcription Kit; Qiagen,
Crawley, West Sussex, UK) and random hexamers (Invitrogen)
were used to produce cDNA. Generation of a fluorescently
labelled PCR product of both genomic DNA (gDNA) and cDNA
was performed in both case and controls (suitable case material
was available from only one patient with vCJD) using sense 59-
FAM-AGGTGCGCGGGGCAGT-39 (8296–8311) and antisense
59-CTCACGCGCACCCTCGA-39 (8348–8364) primers. The
resultant 69 bp amplicon was separated by electrophoresis on
an automated sequencer (3130xl; Applied Biosystems) with
LIZ500 size standard and peak size, height and area from both
gDNA and cDNA were calculated using GeneMapper software
V.4.0 (Applied Biosystems).
Statistical analysis
Statistical and genetic analyses were performed using
Haploview,
23 PLINK (http://pngu.mgh.harvard.edu/,purcell/
plink/index.shtml) and SSPS software. For sCJD, the analysis
was 80% powered to detect a heterozygous genotype relative
risk of 1.25 in a multiplicative model. Haplotype frequencies
were estimated with an expectation–maximisation (EM)
algorithm.
RESULTS
Six different genetic variations were detected in the 2766
chromosomes sequenced (table 1). Of these, three were of an
insertion or deletion (indel) variety, two were non-coding
single-nucleotide polymorphisms (SNPs) either inside or outside
the SPRN ORF, and one was a coding SNP. This common
missense variant was found in the SPRN signal peptide sequence
(c.20CRT, p.T7M), and is linked to a GRA transversion 11 bp
59 of the SPRN translation start methionine. We found 59-11A
linked to p.7M and 59-11G linked to p.7T. These alleles form the
basis of derived haplotypes designated *1 and *2 respectively
(table 1). Within this haplotype scheme, the *1 related
haplotypes were all associated with c.20T and c.183C of the
SPRN ORF, whereas the *2 related haplotypes were associated
with c.20C and either position c.183C (haplotypes *2A and *2C)
or c.183T (haplotypes *2 and *2C). A 12 bp deletion variation
was also detected in four healthy controls (three on the *1
haplotype and one on the *2 haplotype), corresponding to the
in-frame deletion of an AAAG amino acid repeat motif located
in the highly conserved hydrophobic central domain of Sho,
reducing the polypeptide chain to 147aa from the most
commonly observed length of 151aa. These variants were
designated haplotypes *1A and *2C respectively. A second
similar indel variation was detected in a single CEPH control,
and involved a 12 bp insertion in the hydrophobic domain
resulting in an additional AAAG amino acid repeat motif,
increasing the full length protein to 155aa, and was designated
haplotype *1B. The third indel variation detected in two
patients with vCJD only was an insertion of a single guanine
base pair at codon 46. This frameshift mutation creates a
potential extended ORF of 882 bp, designated haplotype *2B.
Positive results of statistical analysis between genotypes and
alleles of cases versus controls are shown in table 2.
The SNPs 59-11ARG and c.20TRC were found to be in
complete linkage disequilibrium and were therefore grouped. A
genotypic model gave p=0.028, and an allelic model gave
p=0.009, comparing sCJD with controls where an increase of
59-11A and linked c.20T was observed in cases. A similar
increase was observed in vCJD cases although the small
numbers meant this did not reach significance. An allelic model
was used with the Fisher Exact test when analysing the level of
significance of the frameshift allele detected in two vCJD cases
(p=0.01, table 2).
SPRN genotype data was also stratified by PRNP codon 129
status (table 3). No significant association was found between
control codon 129 status and SPRN genotype and therefore
control data is shown unstratified. Stratification of sCJD SPRN
genotype by codon 129 status showed a strongly significant
association between c.20T and codon 129 methionine homo-
zygous sCJD (p=0.007). Further stratification of SPRN
Table 3 Stratification of SPRN genotypes in patients
with sporadic Creutzfeldt–Jakob disease
Genotype
c.20 Control
sCJD
MM MV VV
TT 375 131 50 29
TC 405 98 31 41
CC 81 16 8 8
p Value – 0.007 0.038 0.67
sCJD, sporadic Creutzfeldt–Jakob disease.
Because SPRN SNPs at positions intron 1 59-11 and c.20 show
complete linkage, the genotypes shown are representative of either
genotype 59-11A/59-11G, or c.20T/c.20C.
Table 4 Stratification of phenotypic data in patients with variant Creutzfeldt–Jakob disease
Genotype
c.20
Age at disease onset (years) Duration of disease (months) Year of onset
Mean SD Median Mean SD Median Mean SD Median
TT 29.9 12.2 28 16.6 5.8 16 1998.4 2.4 1999
TC 29.6 10.3 25 15.7 5.2 14.5 1999.0 2.4 1999
CC 33.5 9.8 29 19.5 8.4 19 1998.6 2.6 1998
SD, standard deviation.
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disease, duration and year of onset as a measure of susceptibility
within the vCJD group (table 4), but no significant associations
with these aspects of phenotype were detected. Finally, sCJD
SPRN genotype data was stratified by age at onset and duration
of disease and PrP
Sc type (table 5). Again, no significant
associations were detected.
Unfortunately, RNA recovered from the single vCJD case
possessing the frameshift mutation was of insufficient quality
for our assessment of expression level of mutant transcripts.
The year of death of the two frameshift mutation patients with
vCJD was 1996 and 1995, towards the start of the vCJD
epidemic. The clinical history of the patient who died in 1996
and was examined in detail involved depression, behavioural
disturbance, altered mood with emotional lability, cognitive
decline and progressive chorea of 12 months’ duration. Clinical
examination was notable for global rigidity, generalised chorea,
a broad-based gait and attentional deficits. This patient died
aged 28 years. Fewer details are available for the second patient
with vCJD with the frameshift mutation who died aged
29 years.
DISCUSSION
We report sequencing of the SPRN ORF in all available samples
of UK patients with vCJD, 415 patients with definite or
probable sCJD and 861 healthy controls. We found a significant
association between a frameshift mutation and vCJD (p=0.01)
and between c.20T and sCJD (p=0.009). Three major
haplotypes exist in the healthy control sample set tested and
are defined by the three SNPs detected: A/T/C, G/C/T, G/C/C
(59-11/c.20/c.183, respectively). Haplotype frequencies were
approximately 0.69, 0.21, and 0.10 for these haplotypes,
respectively (averaged from cases and controls; table 1).
Additional haplotypes exist at low frequency and are associated
with indel variations of the hydrophobic core in healthy
controls and with a frameshift mutation in two patients with
vCJD. Given the low frequency of indel variants discovered in
healthy controls, it is not surprising that we did not detect a
similar polymorphism in the cases tested.
Our investigations have revealed genetic variants that were
discovered in cases only, cases and controls, or controls only.
The effect of these variants on Sho biology or prion biology is
unknown, but the nature of each and their location within
SPRN may provide insight into their likely functionality. The
indel variations discovered in five healthy controls all affect the
size of the hydrophobic core of the Sho protein from the most
common size of 23aa to either 19aa or 27aa depending on alleles
containing a 12 bp deletion or insertion respectively. Missense
mutations of the hydrophobic core of PrP are associated with
disease and have been shown to lead to a transmembrane
topological variant of PrP with the C-terminus being luminal
and the N-terminus cytoplasmic.
24 The significance of expan-
sion or contraction of the hydrophobic core by insertion or
deletion of 4aa in Sho remains unknown, although our finding
of such variants in healthy controls suggests toleration of these
in Sho.
The allele we report associated with sCJD, for which we also
report a trend towards the same allele in vCJD, has two genetic
variations that determine haplotype in our scheme. 1* haplo-
types are associated with 59-11A/c.20T (p.7M) and we have
shown that these are significantly more common in sCJD. It
remains possible that either 59-11ARG or c.20TRC are
functional SNPs, or indeed that an as yet undetermined
functional polymorphism exists in unscreened regions of
SPRN. The SNP 59-11ARG is located in the short 16 bp
untranslated region (UTR) of SPRN exon 1 and has a
probability of 0.82 that alternative splicing may occur when
guanine is present at bp 59-11 as determined by Netgene2 (http://
www.cbs.dtu.dk/services/NetGene2/) analysis. Conversely, no
alternative splicing is predicted for 59-11A. The biological effect of
excision of 5 bp of 59UTR close to the ORF is unknown, and
further complexity exists in deciphering the functional element
linked to sCJD due to c.20CRT. In this, an increase of the p.7M
allele was found in sCJD, and codon 7 is predicted to be contained
within the signal peptide sequence of SPRN. The frequency of
these alleles in healthy controls is strongly suggestive that no
deleterious transport of Sho occurs due to methionine at residue 7
of the signal sequence, but this does not obviate the effect of
subtle influences on protein transport upon establishment and
progression of prion disease. Indeed, in a mouse model exploring
the role of mutations in the signal peptide sequence of PrP on
hydrophobic tract mutants, it has been shown that the double
mutant L9R-3AV resulted in abnormal PrP trafficking.
25
The effects of our final finding of a significant association of a
frameshift mutation with vCJD is more easily rationalised.
Insertion of a single guanine at codon 46 of SPRN would cause a
putative polypeptide chain of 294aa if translation of mutant
transcript occurred, and a corresponding reduction in normal
Sho protein. Nonsense-mediated mRNA decay (NMD) is a
mechanism by which transcripts containing premature transla-
tion termination codons are degraded,
26 and as most frameshift
mutations result in the presence of a premature termination
codon, most mRNA transcripts containing a frameshift muta-
tion are predicted to be degraded by NMD. Despite our efforts
to assess the levels of the p.Ala46GlyfsX294 message from
frontal cortex tissue of a single patient with vCJD, owing to
prolonged post-mortem delay and several sample freeze–thaw
cycles we were unable to show whether or not the transcript
exists at all, or whether it exists at reduced or equal measure to
the wild-type allele. Nevertheless, the presence of a rare
frameshift allele in two patients with vCJD remains of interest,
particularly as these patients were amongst the most suscep-
tible patients based on time of onset and were among the first
British patients. In all other respects, the phenotype of these
two cases was unremarkable within the larger vCJD cohort. The
possibility that these two patients, who resided in different
Table 5 Stratification of phenotypic data by PrP
Sc (molecular strain) type (according to the London
classification
27), according to SPRN genotypes in patients with sporadic Creutzfeldt–Jakob disease
Genotype
c.20
Age at disease onset (years) Duration of disease (months) PrP
Sc type
12 3 2 + 3 Mean SD Median Mean SD Median
TT 55.3 21.5 62 9.1 13.6 5 6 33 9 2
CT 52.8 23.3 61 6.6 7.5 4 5 17 11 0
CC 57.3 27.2 68 7.3 4.8 7 1 3 1 0
SD, standard deviation.
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wide genotype data (500K arrays; Affymetrix, Santa Clara,
California, USA; data not shown). More definitive genetic
evidence that SPRN null alleles cause susceptibility to vCJD
would require an allelic series, which we were unable to show
with our necessarily small sample size.
Although confirmation of our findings in further non-UK
cases of vCJD and sCJD would be extremely valuable, our data
support the hypothesis that SPRN genetic variants are involved
in the pathobiology of prion disease. Interactions between PrP
and Sho in health and disease are not yet clear, but these genetic
data are consistent with an existing model that proposes a
neuroprotective role for Sho.
3 Our associations of a frameshift
mutation, which may lead to a null allele, with vCJD, and *1
SPRN haplotypes with sCJD, are consistent with a direct or
indirect interaction between proteins in the disease process.
However, the genetic evidence is not straightforward in that
different alleles were associated with two categories of human
prion disease. Whether this finding relates to our necessarily
small sample sizes, as the c.20T allele was more common, but
not significantly so, in vCJD, or alternatively reflects the
distinct pathogenesis of sporadic and vCJD, is unresolved.
Further investigations are required to explore these possibilities,
and in particular, creation of null or transgenic cellular or mouse
models of SPRN.
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